Sodium Stibogluconate (SSG) — Competitive Intelligence Brief

Sodium Stibogluconate (SSG) (Sodium Stibogluconate (SSG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic agent. Area: Infectious Disease.

phase 3 Antiparasitic agent Leishmania glycolytic enzymes; reactive oxygen species generation Infectious Disease Small molecule

Target snapshot

Sodium Stibogluconate (SSG) (Sodium Stibogluconate (SSG)) — U.S. Army Medical Research and Development Command. Sodium stibogluconate is a pentavalent antimony compound that kills Leishmania parasites by generating reactive oxygen species and inhibiting their glycolytic enzymes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sodium Stibogluconate (SSG) TARGET	Sodium Stibogluconate (SSG)	U.S. Army Medical Research and Development Command	phase 3	Antiparasitic agent	Leishmania glycolytic enzymes; reactive oxygen species generation
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	Galderma R&D	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)
Pyrimethamine (PYR)	Pyrimethamine (PYR)	Erasmus Medical Center	marketed	Antifolate antimalarial and antiparasitic agent	Dihydrofolate reductase (DHFR)
Atovaquone Oral Suspension	Atovaquone Oral Suspension	University of Oxford	marketed	Antiparasitic agent	Cytochrome bc1 complex (Complex III)
Antimoniate of N-methylglucamine	Antimoniate of N-methylglucamine	University of Brasilia	marketed	Antiparasitic agent	Leishmania glycolytic enzymes and mitochondrial function
Ivermectin 1% cream	Ivermectin 1% cream	Insel Gruppe AG, University Hospital Bern	marketed	Antiparasitic agent	Glutamate-gated chloride channels
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic agent class)

1. Actavis Inc. · 2 drugs in this class
2. Galderma R&D · 1 drug in this class
3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
4. Padagis LLC · 1 drug in this class
5. U.S. Army Medical Research and Development Command · 1 drug in this class
6. University of Brasilia · 1 drug in this class
7. University of Oxford · 1 drug in this class